IL10 and COVID-19: Increasing IL-10, Th1 suppression, and suppression of IL-6 level by tocilizumab used during the cytokine storm period increase the risk of invasive pulmonary aspergillosis, which progresses with a cavity and has a very poor prognosis in the follow-up period in COVID-19 patients [54–55].